Antimicrobial resistance
- USP global public policy position: addressing antimicrobial resistance
- AMR Challenge: Combatting global antimicrobial resistance
- Advancing Quality of Medicines to Combat Antimicrobial Resistance
- USP Statement to the 74th World Health Assembly Agenda Item 13.5: Antimicrobial resistance
- Antimicrobial Resistance action
Cannabis
Compounding
- USP quality standards for compounding
- Ensuring patient safety in compounding of medicines
- Compounding legal backgrounder
COVID-19
- USP applauds bipartisan leadership on PREVENT Pandemics Act
- USP Statement to the 73rd World Health Assembly Agenda Item 3: Address by WHO Director-General, devoted to the COVID-19 pandemic response
- USP Statement to the 74th World Health Assembly Agenda Item 16.1: COVID-19 Response
Excipients
Falsified and substandard medicines and medical products
- Combatting substandard and falsified medicines
- USP Statement to the 74th World Health Assembly Agenda Item 13.6: Substandard and falsified medical products
- USP Statements to the 72nd World Health Assembly Agenda Item 12.2: Member State mechanism on substandard and falsified medical products
- Member State mechanism on substandard and falsified medical products
Foods
Generic medicines
Monographs
Opioids
Procurement and access
- Assuring Quality in Medicines Procurement
- September 2020 – USP Statement to the 73rd Session of WHO Regional Committee for South-East Asia on access to medicines
- USP Statements to the 72nd World Health Assembly Agenda Item 11.7: Access to medicines and vaccines
- WHO's Roadmap on Access to Medicines and Vaccines
Quality-assured medicines
- USP Statements to the 72nd World Health Assembly Agenda Item 11.8: Follow-up to the high-level meetings of the United Nations General Assembly on health related issues
- May 2018 - Statements to the 71st World Health Assembly on prevention and control of non-communicable diseases and ending tuberculosis
Regulatory system strengthening
- September 2018 - Statement to the 71st Session of WHO Regional Committee for South-East Asia on efforts to strengthen the health workforce
- USP Statement on the World Health Organization's (WHO) Publication: Delivering Quality-Assured Medical Products for All 2019-2023 – WHO's Five-Year Plan to Help Build Effective and Efficient Regulatory Systems
Supply chain
Collaboration with FDA
USP and FDA work together to make medicines, dietary supplements and food ingredients in the US among the safest in the world.
Building trust in generic medicines
We can help increase patient access to medicines by facilitating generics competition through, training and education, and collaborations.